In recent days, the network of officials of the national bureau of medicine and medicine has shown that the application for sodium injection rehydration from the henan yunhong pharmaceuticals was approved and evaluated for consistency. At the same time, the recent publication of the ninth national inventory of the central procurement of medicines by national organizations indicates that the drug has been included in the collection。
In fact, the price of sodium phosphate injections has risen in some areas this year to between a dozen and a hundred dollars. In an interview with the representative of the national people's congress in beijing and secretary of the party of the first people's hospital of changzhou city, rey tokyu, said: “the original price of the disemison (injection fluid) was $0. 35/salary, rising to $ 98. 76/salary in 2022, nearly 282 times the price.” this increase is remarkable。
In addition, data from the central comchis show that the size of the sale of the dispensary in 2022 reached 853 million yuan, an increase of 58. 2 per cent over the same period. In particular, in the first half of this year, the drug was sold at a national level of nearly 800 million, an increase of 101 per cent over the same period, and has been sold for almost six months throughout last year。
Sales at the national level hospital in disenmezon
Source: central chis
However, as an old drug, sodium phosphate injection fluids from the disenthion were initially produced at a low cost and sold at a low cost, with sales remaining at around tens of millions over the years. The significant increase in sales in recent years is partly due to the rise in unit prices for the products of enterprises。
In addition to price increases for raw materials, industry researchers have indicated that the price increase for this round of medicines was due to the fact that, following the liberalization of the maximum retail price limit in 2015, many enterprises moved from wait-and-see to action and began to raise prices successively in 2016; at the same time, a range of policies at the national policy level, such as the evaluation of pharmaceutical consistency and flight inspections, have also led to higher production and circulation costs for enterprises. According to research papers published in chinese medicines, the reasons for the increase in prices of essential medicines include, but are not limited to, higher production costs, higher supply prices for producers, inability to meet the two-vote system and higher prices for raw materials。
In fact, sodium phosphate injection fluids in the country have production approvals in over 100 enterprises, and at present nine enterprises have been evaluated: the qingin medicine industry, the chengdubet drug industry, the tianjin ginyu pharmaceutical industry, the zhejiang jinxi pharmaceutical industry, the guangzhou green cross pharmaceutical industry, the hubei tianxi pharmaceutical industry, the southwest pharmaceutical industry and the henan yunhong pharmaceutical industry. In addition, nearly 10 enterprises submitted additional applications for conformity evaluation and new classification simulations for listing. The pre-bid competition pattern is expected to break 10。
After the sodium phosphate injection is integrated into the national collection, prices will stabilize and supplies will be secure, although it may be difficult to see sodium phosphate injections for a few cents。
